Most Read Articles
26 Jun 2020

Achieving standard of care targets, such as reduced levels of low-density lipoprotein cholesterol and glycated haemoglobin, improves outcomes in coronary heart disease patients, a new study has found.

Pearl Toh, 19 Jan 2018
Blood pressure (BP) control can be best achieved with a multilevel, multicomponent approach involving team-based care with physician- and non-physician-led interventions, as well as patient-level strategies, according to findings of a meta-analysis.
Dr. Joseph Delano Fule Robles, 24 Jul 2018

Functional foods benefit the body beyond its nutritional effects, with studies showing that they can improve general state of health and reduce the risk of diseases.

29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Unfractionated heparin for venous thromboembolism ups risk of bleeding in obese patients

30 Jun 2020

In morbidly obese hospitalized patients, high-fixed dose unfractionated heparin for the prevention of venous thromboembolism is associated with a higher risk of major bleeding events compared with high-fixed dose enoxaparin, a recent study has shown.

Of the 305 patients included, 190 received unfractionated heparin and 115 enoxaparin. The incidence of major bleeding was significantly higher among patients on unfractionated heparin (odds ratio [OR], 1.85, 95 percent confidence interval [CI], 1.07–3.13; p=0.025). No significant difference was seen in the incidence of venous thromboembolism diagnosed during hospitalization.

Intensive care acuity (OR, 3.32, 95 percent CI, 1.91–5.78; p<0.001) and selection of unfractionated heparin rather than enoxaparin for venous thromboembolism prophylaxis (OR, 2.16, 95 percent CI, 1.22–3.82; p=0.008) were independently predictive of major bleeding.

In this single-centre retrospective, observational study, the authors identified hospitalized patients who were morbidly obese (body mass index, ≥40 kg/m2) and who received either high-fixed dose enoxaparin (40 mg every 12 hours) or unfractionated heparin (7,500 units every 8 hours) for venous thromboembolism prophylaxis.

Incidence of major bleeding and venous thromboembolism diagnosed during hospitalization were the co-primary endpoints. Multivariable regression was used to determine the predictors of major bleeding.

“Venous thromboembolism is a cause of morbidity and mortality in hospitalized patients, and morbid obesity increases this risk,” the authors said.

“Various prophylaxis dosing strategies have been investigated, [but] it [was] unclear if high-fixed dose enoxaparin or high-fixed dose unfractionated heparin thromboprophylaxis [was] optimal for minimizing the incidence of major bleeding and reducing hospital-acquired venous thromboembolism,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Jun 2020

Achieving standard of care targets, such as reduced levels of low-density lipoprotein cholesterol and glycated haemoglobin, improves outcomes in coronary heart disease patients, a new study has found.

Pearl Toh, 19 Jan 2018
Blood pressure (BP) control can be best achieved with a multilevel, multicomponent approach involving team-based care with physician- and non-physician-led interventions, as well as patient-level strategies, according to findings of a meta-analysis.
Dr. Joseph Delano Fule Robles, 24 Jul 2018

Functional foods benefit the body beyond its nutritional effects, with studies showing that they can improve general state of health and reduce the risk of diseases.

29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.